Tag: FDA breakthrough designated myeloma drug

Off-the-shelf Immune Drug for Aggressive Multiple Myeloma: Teclistamab

U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for teclistamab in the treatment of relapsed or refractory multiple myeloma. This follows a PRIME (PRIority MEdicines) designation from the European Medicines Agency (EMA) received earlier this year. …